Stock ALBPS BIOPHYTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Biophytis S.A.

Equities

ALBPS

FR0012816825

Market Closed - Euronext Paris
Other stock markets
 11:35:28 2024-04-18 am EDT 		5-day change 1st Jan Change
0.0024 EUR +4.35% Intraday chart for Biophytis S.A. -7.69% -52.94%
Apr. 18 Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity CI
Apr. 17 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
Biophytis : une demande de brevet déposée dans l'obésité
Biophytis S A : investit le marché de l'obésité
Biophytis S A : Communique de Presse
Biophytis S A : Communique de Presse
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
Top Premarket Gainers
Biophytis : une étude clinique lancée dans l'obésité
Biophytis Flags 'Significant Doubt' Over Ability to Continue Operations; to Launch Phase 2 Obesity Trial; Shares Rise Pre-Bell
On s'occupe comme on peut
En Direct des Marchés : EsssilorLuxottica, Bouygues, Atos, BioMérieux, UBS, Eli Lilly, L'Occitane...
Biophytis S A : lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALBPS Stock
  4. News Biophytis S.A.
  5. Other languages